Efficacy and safety of maintenance immune checkpoint inhibitors with or without pemetrexed in advanced non-squamous non-small cell lung cancer: a retrospective study

Article Oncology

Impact of maintenance therapy following induction immunochemotherapy for untreated advanced non-small cell lung cancer patients

Ryota Nakamura et al.

Summary: This study found that response to prior immunochemotherapy was associated with clinical outcomes among patients with advanced NSCLC who received maintenance therapy.

JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2022)

Add to Collection

Article Oncology

First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open-label, phase 3 trial

Luis Paz-Ares et al.

Summary: The combination of first-line nivolumab plus ipilimumab with a limited course of chemotherapy showed a significant improvement in overall survival for patients with advanced non-small-cell lung cancer, supporting it as a new treatment option for this patient population.

LANCET ONCOLOGY (2021)

Add to Collection

Article Critical Care Medicine

Camrelizumab plus carboplatin and pemetrexed versus chemotherapy alone in chemotherapy-naive patients with advanced non-squamous non-small-cell lung cancer (CameL): a randomised, open-label, multicentre, phase 3 trial

Caicun Zhou et al.

Summary: The study showed a statistically significant and clinically meaningful improvement in progression-free survival with camrelizumab plus chemotherapy compared to chemotherapy alone, making it a promising first-line treatment option for Chinese patients with advanced non-squamous NSCLC without EGFR and ALK alterations, with further long-term outcomes and confirmatory testing still ongoing.

LANCET RESPIRATORY MEDICINE (2021)

Add to Collection

Article Oncology

Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries

Hyuna Sung et al.

Summary: The global cancer burden in 2020 saw an estimated 19.3 million new cancer cases and almost 10.0 million cancer deaths. Female breast cancer surpassed lung cancer as the most commonly diagnosed cancer, while lung cancer remained the leading cause of cancer death. These trends are expected to rise in 2040, with transitioning countries experiencing a larger increase compared to transitioned countries due to demographic changes and risk factors associated with globalization and a growing economy. Efforts to improve cancer prevention measures and provision of cancer care in transitioning countries will be crucial for global cancer control.

CA-A CANCER JOURNAL FOR CLINICIANS (2021)

Add to Collection

Article Oncology

Non-Small Cell Lung Cancer, Version 2.2021 Featured Updates to the NCCN Guidelines

David S. Ettinger et al.

Summary: The NCCN Guidelines for NSCLC cover all aspects of management, with recent updates focusing on targeted therapies, immunotherapies, and their respective biomarkers.

JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2021)

Add to Collection

Editorial Material Oncology

From CheckMate 227 to CheckMate 9LA: rethinking the status of chemotherapy in the immunotherapy era-chemo-free or chemo-reform?

Haiyi Deng et al.

TRANSLATIONAL LUNG CANCER RESEARCH (2021)

Add to Collection

Article Oncology

Tislelizumab Plus Chemotherapy as First-Line Treatment for Locally Advanced or Metastatic Nonsquamous NSCLC (RATIONALE 304): A Randomized Phase 3 Trial

Shun Lu et al.

Summary: The addition of tislelizumab to chemotherapy in patients with advanced nonsquamous NSCLC resulted in significantly prolonged progression-free survival (PFS), higher response rates, and longer response duration compared with chemotherapy alone, indicating a promising new option for first-line treatment regardless of disease stage.

JOURNAL OF THORACIC ONCOLOGY (2021)

Add to Collection

Article Medicine, Research & Experimental

Genomic and transcriptional alterations in first-line chemotherapy exert a potentially unfavorable influence on subsequent immunotherapy in NSCLC

Yayi He et al.

Summary: Recent studies have shown that first-line immunotherapy in NSCLC patients leads to better therapeutic response compared to second-line treatment. This study found that first-line chemotherapy can influence the tumor microenvironment and decrease the efficacy of subsequent immunotherapy in NSCLC patients without TKI-related driver gene mutations. The study provides insights into the mechanisms behind the unsatisfactory results of immunotherapy given after chemotherapy in NSCLC.

THERANOSTICS (2021)

Add to Collection

Review Oncology